We have downgraded Kongsberg Gruppen to SELL (HOLD) and lowered our target price to NOK1,250 (1,450). We believe the 2025e P/E of 46x overstates its growth capabilities 1) on an absolute basis, in a scenario where all of NATO reaches defence spending of 3.3% of GDP; and 2) compared to other defence companies as, in our view, the market appears to miss that only 20% of its 2024 sales were from European defence spending.
A director at Castellum AB bought 1,008 shares at 110.850SEK and the significance rating of the trade was 35/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.
The solid Q1 results included a 6% EBITDA beat, led by record-high sales and profits from growing agricultural product sales – management said the underlying trend was driven by demand for ‘green’ food production products. Our 2026–2027e EPS are largely unchanged (tweaked by c1%) as the USD depreciation and lowered bioethanol price guidance largely offset the higher agricultural product sales. We still see this as an attractive entry point, and reiterate our BUY and NOK230 target price.
Borregaard ASA: EBITDA1 of NOK 511 million in the 1st quarter Borregaard’s operating revenues increased to NOK 2,036 million (NOK 1,975 million)2 in the 1st quarter of 2025. EBITDA1 reached NOK 511 million (NOK 442 million). The result in BioSolutions increased, BioMaterials had a result in line with the corresponding quarter last year and Fine Chemicals had a lower result. Strong sales to agriculture were the main reason for the all-time high result in BioSolutions. For BioMaterials, higher sales prices were offset by lower sales volume, increased wood costs, and cost increases in general...
A solid Q1 report included orders and sales up 10% and 3% organically YOY, respectively, and an adj. EBIT margin of 19.9%; however, this included a 190bp FX boost, and we believe underlying margins could remain under pressure until the service mix improves. Albeit with increased uncertainty, management guided for mining demand to remain strong but construction to remain weak near-term. We have trimmed our 2025–2027e sales and adj. EBIT by 2% (FX-related) but reiterate our HOLD and SEK220 target ...
The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.